respiratory syncytial virus immune globulin

Indications: - prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV) in children < 24 months of age with bronchopulmonary dysplasia (BPD) or a history of premature birth (< 35 weeks gestation) Contraindications: 1) selective IgA deficiency 2) history of severe reaction to immune globulin pregnancy-category C safety in lactation ? Dosage: - 750 mg/kg/month - 1.5 mL/kg/hr IV for 15 minutes - increase to 3 mg/kg/hr IV for another 15 minutes - 6 mL/kg/hr IV until completion of dose IV administration only: 2500 mg RSV IgG/50 mL vial. Pharmacokinetics: elimination: plasma Adverse effects: 1) most common (1-10%) - rash, tachycardia, hypertension, hypotension, fever, fluid overload, vomiting, diarrhea, gastroenteritis, inflammation at injection site, respiratory distress, wheezing, rales, hypoxia, tachypnea 2) uncommon (< 1%) - edema, pallor, heart murmur, cyanosis, flushing, palpitations, chest tightness, dizziness, anxiety, eczema, pruritus, abdominal cramps, myalgia, arthralgia, cough, rhinorrhea, dyspnea

References

Kaiser Permanente Northern California Regional Drug Formulary, 1998